No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Hainan Poly Pharm. Co., Ltd's (SZSE:300630) Shares Bounce 30% But Its Business Still Trails The Industry
*ST Puli (300630.SZ): Has not signed any form of related agreement with USA GPO Premier, Inc.
*ST Puli (300630.SZ) clarifies that as of now, the company has not engaged with USA GPO Premie...
Hainan Poly Pharm (300630.SZ): Major violations have triggered mandatory (Delisted) status. From January 7, it will be subject to "Delisting Risk Warning."
Hainan Poly Pharm (300630.SZ) issued an announcement that the company is suspected of illegal information disclosure and has been investigated by the China Securities Regulatory Commission.
December 10 A-share investment risk avoidance | Shenzhen SDG Service: Shareholder Silver Kun Company and Longxin Construction plan to collectively shareholding not exceeding 2%.
Hainan Poly Pharm: Currently under investigation by the Securities Regulatory Commission. There is a risk of being subjected to compulsory delisting due to major illegal activities involving stocks.
Hainan Poly Pharm (SZSE:300630) Adds CN¥615m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 77%
Investors Holding Back On Hainan Poly Pharm. Co., Ltd (SZSE:300630)
